Ranitidine Use and Gastric Cancer Among Persons with Helicobacter pylori
Authors:
- 15 April 2021
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (5) , 1822-1830
Abstract
Background The Food and Drug Administration requested withdrawal of ranitidine formulations, due to a potentially carcinogenic contaminant, N-nitrosodimethylamine. Aims We evaluate whether ranitidine use is associated with gastric cancer. Methods This is a retrospective multicenter, nationwide cohort study within the Veterans Health Administration, among patients with Helicobacter pylori (HP) prescribed long-term acid suppression with either: (1) ranitidine, (2) other histamine type 2 receptor blocker (H2RB), or (3) proton pump inhibitor (PPI)) between May 1, 1998, and December 31, 2018. Covariates included race, ethnicity, smoking, age, HP treatment, HP eradication. Primary outcome was non-proximal gastric adenocarcinomas, using multivariable Cox proportional hazards analysis. Results We identified 279,505 patients with HP prescribed long-term acid suppression (median 53.4 years; 92.9% male). Compared to ranitidine, non-ranitidine H2RB users were more likely to develop cancer (HR 1.83, 95%CI 1.36–2.48); PPI users had no significant difference in future cancer risk (HR 0.92, 95% CI 0.82–1.04), p < 0.001. Demographics associated with future cancer included increasing age (HR 1.18, 95% CI 1.15–1.20, p < 0.001), Hispanic/Latino ethnicity (HR 1.46, 95% CI 1.21–1.75, p < 0.001), Black race (HR 1.89, 95% CI 1.68–2.14) or Asian race (HR 2.03, 95% CI 1.17–3.52), p < 0.001, and gender (female gender HR 0.64, 95% CI 0.48–0.85, p = 0.02). Smoking was associated with future cancer (HR 1.38, 95% CI 1.23–1.54, p < 0.001). Secondary analysis demonstrated decreased cancer risk in those with confirmed HP eradication (HR 0.24, 95% CI 0.14–0.40). No association between ranitidine and increased gastric cancer was found. Conclusion There is no demonstrable association between ranitidine use and future gastric cancer among individuals with HP on long-term acid suppression.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (5 T32 DK7740-22)
This publication has 41 references indexed in Scilit:
- Helicobacter pylori-induced gastric inflammation and gastric cancerCancer Letters, 2014
- 17β-Estradiol and Tamoxifen Prevent Gastric Cancer by Modulating Leukocyte Recruitment and Oncogenic Pathways inHelicobacter Pylori–Infected INS-GAS Male MiceCancer Prevention Research, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Proton pump inhibitors and risk of gastric cancer: a population-based cohort studyBritish Journal of Cancer, 2009
- Differences in the Pattern of Presentation and Treatment of Proximal and Distal Gastric Cancer: Results of the 2001 Gastric Patient Care EvaluationAnnals of Surgical Oncology, 2008
- Association Between Use of Acid-Suppressive Drugs and Risk of Gastric CancerDrug Safety, 2008
- Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal typeAlimentary Pharmacology & Therapeutics, 2007
- Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UKGut, 2006
- Meningiomas and Gliomas in JuxtapositionAmerican Journal of Surgical Pathology, 1995
- Carcinogenesis in rats by nitrosodimethylamine and other nitrosomethylalkylamines at low dosesCancer Letters, 1984